RESEARCH TRIANGLE, NC—Talecris Bioteherapeutics Holding Corp., a developer of plasma-derived protein therapies, has filed with the U.S. Securities and Exchange Commission for a $1 billion initial public offering of stock.
The company plans to trade on the NASDAQ exchange under the ticker symbol TLCR.

Cerberus Management and Ampersand Ventures control the company.

On the Web: www.talecris.com

Southeast Venture Conference, February 29 – March 1, 2012 at the Ritz Carlton in Tysons Corner, VA – Where Smart Money Meets Smart People.
www.seventure.org

© 2007, TechJournal South. All rights reserved.